0001209191-20-009734.txt : 20200214 0001209191-20-009734.hdr.sgml : 20200214 20200214170100 ACCESSION NUMBER: 0001209191-20-009734 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200205 FILED AS OF DATE: 20200214 DATE AS OF CHANGE: 20200214 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: LEIDEN JEFFREY M CENTRAL INDEX KEY: 0001242825 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 20621576 MAIL ADDRESS: STREET 1: 40 LANDSDOWNE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 4/A 1 doc4a.xml FORM 4/A SUBMISSION X0306 4/A 2020-02-05 2020-02-07 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001242825 LEIDEN JEFFREY M C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 1 1 0 0 CEO & President Common Stock 2020-02-05 4 A 0 50566 0.00 A 156912 D Common Stock 2020-02-05 4 A 0 28444 0.00 A 185356 D Common Stock 2020-02-05 4 A 0 31462 0.00 A 216818 D Common Stock 440 I 401(k) This Amendment to Form 4 is filed solely for the purpose of correcting a clerical error in the transaction date reported in Table I, column 2 on the Form 4 filed on February 7, 2020. The correct transaction date is February 5, 2020 as was reflected in Item 3 of the original filing. Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2017 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/05/2020 and the shares will vest on 02/10/2020. Represents earned performance shares with respect to a performance stock unit award granted on 02/06/2019 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/05/2020 and the shares will vest in installments beginning on 02/24/2020. Restricted stock unit award that will vest pursuant to his employment agreement upon Dr. Leiden's transition from CEO. /s/ Omar White, Attorney-in-Fact 2020-02-14